Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
Voyager Therapeutics (Nasdaq: VYGR) will release its second quarter 2022 financial and operational results after the market closes on August 4, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR) will release its second quarter 2022 financial and operational results after the market closes on August 4, 2022. A live conference call and webcast will occur at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join the call by dialing 1-833-634-2276 (domestic) or 1-412-902-4144 (international). A replay will be available for at least 30 days on its Investors website. Voyager Therapeutics focuses on developing AAV gene therapy treatments for serious diseases with its proprietary TRACER™ capsid platform.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was +6.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022. Subsequently, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss its financial and operating results and provide a corporate update.
The conference call may be accessed by dialing 1-833-634-2276 (domestic) or 1-412-902-4144 (international) and asking for the Voyager Therapeutics earnings call. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay will be available at the same link after its completion. The replay will be available for at least 30 days following the conclusion of the call.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Voyager’s TRACER™ capsid discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
voyagertherapeutics.com LinkedIn Twitter
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.